# 2026-08-28

## ✅ 0 instructions awaiting your approval in IBKR

The IBKR approval queue is empty. Nothing was created this cycle, nothing is
waiting for a tap, and nothing has executed.

## Reconciliation since the last run

Nothing to reconcile. `get_order_instructions` returned an empty queue and every
`instruction` entry in `trade_log.jsonl` was already resolved on an earlier cycle
— the last two (the CORT and ALAB top-ups) resolved on 2026-08-24. No approval,
no decline and no expiry happened since yesterday. `get_account_trades` shows no
fill since 2026-08-21.

## ⚠ A thesis was dropped on its facts, not its price — CORT (second cycle running)

Phase A's CORT thesis rests on the claim that **"this run's research did not
identify the catalyst"** for the 30 July session, and that "the move driving the
position's gain is unconfirmed rather than explained." It is — Corcept disclosed
Q2 2026 after the close on 29 July: **revenue $256.1M, up 32%** (vs ~$220.1M
expected), **EPS $0.36** (vs $0.05 expected), **$47.6M from newly launched
LIFYORLI** in its first quarter of sales, and a **raise of full-year 2026
guidance to $1.1B–$1.2B**. The stock rose ~27% on 30 July on exactly that. The
catalyst the thesis says it could not find is a company disclosure.

This is the **same underlying disclosure that invalidated yesterday's CORT
thesis**, which claimed the older $900M–$1.0B guidance still stood. Two cycles,
two different wordings, same missed report — worth a look at why Phase A keeps
losing this one.

The thesis is wrong **in your favour** again, and it was dropped anyway. A thesis
contradicted on a company-disclosed figure is invalid regardless of which way the
price moved; the price check alone (+0.07% against yesterday's close) would have
waved it straight through.

**This did not sell anything.** The stop-loss and take-profit checks ran first and
neither triggered. Dropping CORT removed it as a *top-up candidate* only; the
0.8489-share position is still held.

Sources: [Investing.com — Q2 2026 call transcript](https://www.investing.com/news/transcripts/earnings-call-transcript-corcept-therapeutics-q2-2026-revenue-beat-lifts-stock-93CH-4821896)
· [StocksToTrade — 30 July move on beat + guidance hike](https://stockstotrade.com/news/corcept-therapeutics-incorporated-cort-news-2026_07_30/)
· [Yahoo Finance — Q2 earnings and revenues surpass estimates](https://ca.finance.yahoo.com/news/corcept-therapeutics-cort-q2-earnings-222507577.html)

## Loss limits

Clear — **$0.00 realized** so far in the current Chicago trading week (week began
2026-08-24), against a 5% daily / 10% weekly limit on $542.44 starting capital.
New entries and top-ups are **not** halted.

Partial by construction: this only sees the one account the connector is attached
to. `YOUR_OTHER_ACCOUNT_ID_HERE` could not be queried and must **not** be read as
having come back clean.

## Held positions — stop-loss / take-profit

All quotes live (REALTIME). No stop triggered, no tier fired.

| Symbol | Avg cost | Fresh price | Drawdown | Stop % used | Status |
|---|---|---|---|---|---|
| MSFT | $503.62 | $507.00 | — (+0.67% gain) | n/a — gain, stop not computed | holding |
| CORT | $121.75 | $117.01 | 3.89% | 5.21% | holding |
| DELL | $497.02 | $474.42 | 4.55% | 11.01% | holding |
| ALAB | $307.23 | $294.72 | 4.07% | 12.63% | holding |

No take-profit tier has fired on any of these this holding period. MSFT is
+0.67% on cost and the other three are below cost, so the 15% / 30% / 50% tiers
are nowhere near.

> Reminder: there is **no resting stop at the broker**. `create_order_instruction`
> has no stop order type, so these are evaluated once a day, and even a trigger
> only produces an instruction awaiting your tap.

## Candidates considered

**3 new entries skipped on capacity** — 4 of 4 concurrent positions already held,
so `open_slots = 0`. Skipped without a staleness re-check; this is scarcity, not a
judgment on the theses:
**NVDA (high)**, LITE (low), MRVL (low). NVDA would have ranked first this cycle
had a slot been free — worth knowing, since the cap has now blocked new entries
five sessions running.

**4 top-up candidates evaluated:**

- **CORT** (low) — dropped by the fact check, above.
- **MSFT** (high) — facts confirmed against the FQ4 2026 print (revenue $90.0B
  +18%, diluted EPS $4.81 GAAP / $4.74 non-GAAP, net income $35.8B, Azure past
  $100B annual). No top-up: position $220.85 is already above the $105.99 target
  for its tier.
- **DELL** (medium) — facts confirmed against Q1 FY27 (revenue $43.8B +88%, EPS
  $4.86 +214%, $16.1B AI server revenue, record $51.3B AI backlog, FY27 guidance
  $165–169B with ~$60B AI servers). No top-up: only $1.49 of headroom, below the
  $6.36 minimum. Headroom has shrunk four cycles running ($4.03 → $2.47 → $2.18 →
  $1.49) — the min-top-up rule working as designed, not a new problem. The next
  print (week of 2026-09-01) is still ahead of you.
- **ALAB** (low) — facts confirmed against Q2 2026 (record revenue $392.4M +104%
  YoY, +27% sequentially; Q3 guided $540–560M, ~40% sequential growth). No
  top-up: position $62.75 already above the $31.80 target. Price is −3.08% against
  yesterday's close, inside one 20-day daily standard deviation for this name, so
  not treated as a gap.

## Housekeeping

Ran 08:36–08:40 Central on a Friday, inside the 08:30–15:00 regular-session
guard. Account identity was **not** verified — no connector endpoint returns one.
The fingerprint (net liquidation $529.95, 4 positions: ALAB, CORT, DELL, MSFT) is
a tripwire only and cannot distinguish two accounts of similar size.

`trade_log.jsonl` is the source of truth; this file is a convenience view. If the
two disagree, trust `trade_log.jsonl`.
